A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

(2020) Inge M. W. Verberk et al.   Alzheimers Research & Therapy

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease

(2019) John C. Morris et al.   JAMA Neurology

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease

(2019) Nicholas J. Ashton et al.   Science Advances

Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2019) Valery L Feigin et al.   LANCET NEUROLOGY

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

(2019) Gil D. Rabinovici et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease

(2019) Leonardo Biscetti et al.   CLINICA CHIMICA ACTA

Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test

(2019) David Wolk et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images

(2019) Subapriya Suppiah et al.   Diagnostics

High-Throughput Mass Spectrometry Assay for Quantifying β-Amyloid 40 and 42 in Cerebrospinal Fluid

(2019) Darren M. Weber et al.   CLINICAL CHEMISTRY

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease

(2019) Pratishtha Chatterjee et al.   JOURNAL OF ALZHEIMERS DISEASE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes

(2018) Inge M.W. Verberk et al.   ANNALS OF NEUROLOGY

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms

(2018) Sebastian Palmqvist et al.   Alzheimers & Dementia

Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays

(2018) Stephen P. Schauer et al.   Alzheimers Research & Therapy

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

(2018) Hedieh Shahpasand-Kroner et al.   Alzheimers Research & Therapy

Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease

(2017) Min Jeong Wang et al.   Alzheimers Research & Therapy

Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry

(2016) Josef Pannee et al.   Alzheimers & Dementia

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics

(2016) Linan Song et al.   Alzheimers Research & Therapy

Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping

(2015) I. van den Broek et al.   CLINICAL CHEMISTRY

Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis

(2015) Elizabeth Morris et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Detection and quantification of plasma amyloid-β by selected reaction monitoring mass spectrometry

(2014) Jun Seok Kim et al.   ANALYTICA CHIMICA ACTA

Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid-  in Cerebrospinal Fluid

(2014) A. Leinenbach et al.   CLINICAL CHEMISTRY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

(2013) Alan Rembach et al.   Alzheimers & Dementia

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

(2013) Jon B Toledo et al.   Alzheimers Research & Therapy

Quantitation of amyloid beta peptides Aβ1–38, Aβ1–40, and Aβ1–42 in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry

(2011) Mary E. Lame et al.   ANALYTICAL BIOCHEMISTRY

pROC: an open-source package for R and S+ to analyze and compare ROC curves

(2011) Xavier Robin et al.   BMC BIOINFORMATICS

Correlation between y-Type Ions Observed in Ion Trap and Triple Quadrupole Mass Spectrometers

(2009) Carly A. Sherwood et al.   JOURNAL OF PROTEOME RESEARCH